Back to News
Apr 7, 2026 12:10 PM

Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal

Gilead Sciences Inc. (NASDAQ:GILD) shares are down on Tuesday as the company announced a $3.15 billion acquisition of Tubulis GmbH.

The Foster City, California-based firm aims to enhance its oncology pipeline. The acquisition adds TUB-040, a promising antibody-drug conjugate (ADC) for the treatment of ovarian cancer, to Gilead’s existing oncology portfolio.

Tubulis currently has two programs in clinical trials for solid tumor indications.

Gilead agreed to pay Tubulis for $3.15 billion in upfront cash, with additional contingent milestone payments of up to $1.85 billion.

Evotec SE (NASDAQ:EVO), which holds a 3.14% equity stake in Tubulis, is expected to receive some $100 million in upfront consideration upon closing.

The company is also eligible to receive up to approximately $58 million in additional contingent consideration in line with its equity participation and subject to the achievement of specified milestones.

Evotec took part in Tubulis' 60 million euros Series B financing ...